### 1 Surgical Treatments for Lumbar Spine Diseases: A Systematic Review and Meta-Analysis

# 2 Kanthika Wasinpongwanich<sup>1</sup> · Tanawin Nopsopon<sup>2</sup> · Krit Pongpirul<sup>2,3,4</sup>

- <sup>1</sup> Department of Orthopedics, Faculty of Medicine, Suranaree University of Technology, Nakhon Ratchasima,
- 4 Thailand
- 5 <sup>2</sup> Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok,
- 6 Thailand
- 7 <sup>3</sup> Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 8 <sup>4</sup> Bumrungrad International Hospital, Bangkok, Thailand
- 9

# 10 Corresponding author: Krit Pongpirul

- 11 Email: doctorkrit@gmail.com
- 12

### 13 ORCID ID

- 14 KW: 0000-0002-2649-2846
- 15 TN: 0000-0003-0428-973X
- 16 KP: 0000-0003-3818-9761

# 18 Abstract

**Purpose** Surgical treatment is mandatory in some patients with lumbar spine diseases. To obtain spine fusion, many operative techniques were developed with different fusion rates and clinical results. This study aimed to collect randomized controlled trial (RCT) data to compare fusion rate, clinical outcomes, complications among Transforaminal Lumbar Interbody Fusion (TLIF), and other techniques for lumbar spine diseases.

Methods A systematic literature search of PubMed, Embase, Scopus, Web of Science, and CENTRAL databases was searched for studies up to 13 February 2020. The meta-analysis was done using a random-effects model. Pooled risk ratio (RR) or mean difference (MD) with a 95% confidence interval of fusion rate, clinical outcomes, and complication in TLIF and other techniques for lumbar diseases.

**Results** The literature search identified 3,682 potential studies, 15 RCTs (915 patients) were met our inclusion criteria and were included in the meta-analysis. Compared to other techniques, TLIF had slightly lower fusion rate (RR=0.84 [95% CI 0.72, 0.97], p=0.02,  $I^2=0.0\%$ ) at 1-year follow-up while there was no difference on fusion rate at 2-year follow up (RR=1.06 [95% CI 0.96, 1.18], p=0.27,  $I^2=69.0\%$ ). The estimated risk ratio of total adverse events

31 (RR=0.90 [95% CI 0.59, 1.38], p=0.63,  $l^2=0.0\%$ ) and revision rate (RR=0.78 [95% CI 0.34, 1.79], p=0.56,  $l^2=39.0\%$ )

32 showed no difference. TLIF had approximately half an hour more operative time than other techniques (MD=31.88

33 [95% CI 5.33, 58.44], p=0.02,  $I^2=92.0\%$ ). There was no significant difference between TLIF and other techniques in

34 terms of the blood loss, and clinical outcomes.

35 Conclusions Besides fusion rate at 1-year follow-up and operative time, our study demonstrated similar outcomes of

36 TLIF with other techniques for lumbar diseases in regard to fusion rate, clinical outcomes, and complications.

37 Keywords: Transforaminal Lumbar Interbody Fusion · Lumbar disease · Meta-analysis · Spondylolisthesis ·

38 Degenerative lumbar disease

### 40 Introduction

41 Surgical treatment is mandatory in some patients with lumbar spine diseases. To obtain spine fusion, many operative 42 techniques have been developed with different fusion rates and clinical results. Cloward et al. first described 43 Posterolateral Lumbar Interbody Fusion (PLIF) in 1952 [1] whereas Harm & Rollinger introduced Transforaminal 44 Lumbar Interbody Fusion (TLIF) three decades later [2]. In early 2002, the minimally invasive surgical (MIS) 45 approach was promoted to TLIF by Foley and Lefkowiz to improve peri-postoperative morbidity and clinical results 46 [3]. For anterior lumbar interbody fusion has a long history in the tuberculous spine however the technique was 47 adapted to other lumbar spine diseases [4]. Ozgur et al. describe a novel spine procedure called the Extreme Lateral 48 Interbody Fusion or XLIF in 2006 [5].

Several systematic reviews compared either MIS TLIF or Open TLIF with other techniques e.g. MIS vs open TLIF/PLIF [6], TLIF vs ALIF [7], MIS TLIF vs LLIF [8], TLIF vs PLIF [9], TLIF vs PLF [10]. The studies were conducted around 2014-2018 [6-8,10-14]. Most of them compared 1 or 2 techniques with TLIF for lumbar spine diseases [6-14]. Half of them concluded the level of evidence on their study was low and need more randomized control trials (RCTs) [6-8,10,15]. The fusion rates, clinical outcomes, and complications among operative techniques for lumbar spine diseases have been inconclusive. As time passed, the learning curve of different techniques was theoretically decreased and more RCTs were recently propagated[16-30].

This systematic review and meta-analysis aimed to offer updated results based on fusion rate, clinical outcomes, and complications between TLIF, decompression alone (no fusion), posterolateral fusion, and other interbody fusion (PLIF, ALIF, XLIF).

#### 59 Methods

This study was conducted following the recommendations of the Preferred Reporting Items of Systematic Reviews
and Meta-Analyses (PRISMA) statement. We prospectively registered the systematic review with PROSPERO
International Prospective Register of Ongoing Systematic Reviews (Registration number: CRD42020186858).

#### 63 Search strategy

A systematic literature search of PubMed, Embase, Scopus, Web of Science, and CENTRAL databases were
 searched for studies published between January 2010 and January 2019. The electronic databases were searched up

to 13 February 2020. The reproducible search strategy was presented in detail in the Supplement. Besides, the
 reference lists of included articles were searched, as well as related citations from other journals via Google Scholar.

#### 68 Study selection

Only randomized controlled trials comparing lumbar interbody fusion with posterolateral fusion and/or other lumbar interbody fusion were anticipated in this review. Inclusion criteria were established as follows: (1) the studies with a population of patient age >18 years old (2) randomized controlled trial investigating lumbar spine disease treated with any Lumbar Interbody Fusion or Posterolateral Fusion or No fusion, (3) the study included at least one outcome (fusion rate, disability and pain or complications, operative time, blood loss, hospital length of stay). Exclusion criteria were (1) biomechanical and cadaveric studies, (2) paper that is not in English, (3) duplicated studies.

The title and abstracts of each study were independently reviewed by 2 authors (KW, TN) to assess for inclusion in the meta-analysis. For studies that meet the inclusion criteria, 2 reviewers (KW, TN) independently reviewed the full manuscripts. Discrepancies between the 2 reviewers were resolved by discussion until reach consensus among the authors. In accordance with PRISMA guidelines, the process is presented in a flow chart [31] (Fig.1)

# 80 Data extraction

The following data items were independently extracted by two authors (KW, TN) from the included studies; study design (author, year, country), study population (number of included patients, age, indication for surgery), Visual Analog Score (VAS) for back and leg pain, Oswestry Disability Index (ODI), parameters concerning operation (operative time, length of hospital stay, blood loss, revision) Complications (total adverse events, infection, dural tear, etc.). Discrepancies were resolved by consensus.

#### 86 Quality assessment

The authors worked independently to assess the risk of bias in the included trials using the Cochrane Risk of Bias tool 2.0 for a randomized control trial study[32]. We assessed the randomization process, deviations from intended intervention, missing outcome data, measurement of the outcome, selection of the reported result. We assigned each domain as a low risk of bias, some concerns, and a high risk of bias. We contacted the authors if there was not enough information to assess. If the trial authors did not respond within 14 days, we conducted the assessment using

available data. We resolved the disagreement through discussion. We presented our risk of bias assessment in Figs.2 and 3.

#### 94 Statistical Analysis

95 The primary outcome was fusion rate, total adverse events, and revision rate. The outcomes measured were the 96 mean difference for VAS back and leg pain, Oswestry Disability Index (ODI) score, operative time, blood loss, 97 length of hospital stay with associated 95% CI. Fusion rate, total adverse events, infection rate, revision rate, dural 98 tear were reported as the risk ratio (RR) with 95% CI. The results of the studies were included in the meta-analysis 99 and presented in a forest plot, which also showed statistical powers, confidence intervals, and heterogeneity. The 100 variability within-a study and between studies was assessed by an  $I^2$  estimate of heterogeneity. We regarded level of 101 heterogeneity for  $I^2$  statistic as defined in chapter 9 of the Cochrane Handbook for Systematic Reviews of 102 Interventions: 0–40% might not be important; 30–60% may represent moderate heterogeneity; 50–90% may 103 represent substantial heterogeneity; 75-100% considerable heterogeneity. The random-effects meta-analysis by 104 DerSimonian and Laird method was used as clinical, methodological, and statistical heterogeneity encountered. 105 Prespecified subgroup analyses by type of comparators were performed. We assessed publication bias by computing 106 each study effect size against standard error and plotted it as a funnel plot to assess asymmetry visually. The 107 significant asymmetry indicated the possibility of publication bias or heterogeneity. The meta-analysis was 108 performed using Revman 5.3 (Cochrane Collaboration, Oxford, UK).

#### 109 **Results**

#### 110 Systematic Review

A systematic search identified 3,682 potential English articles, 1,957 were removed due to duplication. Two reviewers assessed the title and abstracts of 1,725 studies which 144 manuscripts remained for full-text assessment. Eventually, 18 RCTs were met the inclusion criteria. 2 RCTs were considered the same population of the TLIF group therefore one study was excluded from the analysis. The studies which did not report the variation were excluded. A preferred reporting Items for Systematic Reviews and Meta-Analyses diagram is shown in Fig. 1.

There were 15 RCTs included with 915 patients (470 TLIF, 258 PLF, 87 PLIF, 26 ALIF, 29 XLIF, 45 no
fusion). The TLIF group in the 2 studies was in addition to posterolateral fusion (PLF). Publication years ranged

- from 2013 to 2019. Two studies reported outcome 1-year follow-up the other reported at least 2-year follow-up.
- 119 Study characteristics are provided in Table 1.

# 121 **Table 1** Study characteristics

Author	Surgical technique	TLIF, n	Other techniques, n	Follow up
Challier 2017	PLF+TLIF vs PLF	30	30	2у
Christensen	TLIF vs PLF	51	49	1y, 2y
2014				
ElShazly 2013	Discectomy+TLIF vs	15	15	2y
	no fusion			
	Discectomy+TLIF vs	15	15	2у
	Discectomy+PLF			
Etemadifar	PLF+TLIF vs PLF	25	25	1.5m, 3m, 6m
2016				1y, 2y
Fariborz 2016	TLIF vs PLIF	30	30	6m, 1y
	TLIF vs PLF	30	30	6m, 1y
	TLIF vs no	30	30	6m, 1y
	fusion+instrumentation			
Hoff 2016	TLIF vs ALIF	24	26	1y, 3y
Høy 2013 <sup>*</sup>	TLIF vs PLF	51	49	1y, 2y
Høy 2017 <sup>*</sup>	TLIF vs PLF	44	44	1y, 2y, 5-10y
Høy 2019 <sup>*</sup>	TLIF vs PLF	51	49	1y, 2y
Isaacs 2016**	TLIF vs XLIF	26	29	1y, 2y
Jalalpour 2015	TLIF vs PLF	68	67	1y, 2y
Li 2013	TLIF vs PLF	19	18	2-5y
Putzier 2016	TLIF vs PLIF	24	23	1y
Sembrano	TLIF vs XLIF	55	26	1y
2016**				
Yang 2016	TLIF vs PLIF	32	34	3m, 1-2y

122 \*same sample group, \*\*same sample group

### 124 Quality assessment

125 For the risk of bias assessment, the included randomized controlled trials had a relatively high percentage of low risk 126 in the randomization process and deviations from intended intervention domains. All included RCTs had some 127 concerns risk of bias on measurement of the outcome. There was some high risk of bias in deviations from intended 128 interventions and selection of the reported result domains. Detailed risk-of-bias assessment for included randomized 129 controlled trials was provided in Fig. 2. A summary of the percentages of RCTs which were at low, some concerns, 130 and high risk for each risk of bias domain wwaspresented in Fig. 3. The funnel plots showed no significant 131 asymmetry which highlighted no evidence of publication bias on the fusion rate, total adverse events, and revision 132 rate. (Supplementary File 1).

#### 133 Meta-analysis

A total of 15 included studies were included in the meta-analysis with 915 patients (470 TLIF, 258 PLF, 87 PLIF, 26
ALIF, 29 XLIF, 45 no fusion).

#### 136 Fusion rate

Fusion rate was 72.7% on TLIF group at 1 year follow up whereas 87.03% fusion rate was reported on other techniques. TLIF had slightly lower fusion rate at 1 year follow up compared to other techniques (RR=0.84 [95% CI 0.72, 0.97], p=0.02,  $l^2=0.0\%$ ) (Fig. 4). However, the fusion rate at 2 years was not shown any statistically significant differences (RR=1.06 [95% CI 0.96, 1.18], p=0.27,  $l^2=69.0\%$ ) as shown in Fig. 5.

### 141 Complications: total adverse events, revision, infection, and dural tear

Total adverse events were reported in 10 studies. TLIF had similar total adverse events compared with PLIF, XLIF and no fusion group (RR=0.90 [95% CI 0.59, 1.38], p=0.63,  $I^2=0.0\%$ ) as shown in Fig. 6. For the revision needed after surgical procedures, the results indicated a different revision rate among groups. (RR=0.78 [95% CI 0.34, 1.79], p=0.56,  $I^2=39.0\%$ ) as shown in Fig. 7.

Infection was reported in 6 studies, overall infection was similar among groups (RR=1.78 [95%CI 0.58,
5.46], *p*=0.31, *I*<sup>2</sup>=0.0%). More infection reported in the TLIF group but was not statistically significant. The dural

- tear was higher in other techniques esp. XLIF group but not reach statistically significant (RR=1.19 [95% CI 0.49,
- 149 2.89], p=0.70,  $l^2=0.0\%$ ). The results of secondary outcomes were reported as shown in Table 2.

### 150 **Operative time**

- 151 ALIF, PLF, no fusion group has shorter operative time whereas PLIF has longer operative time compared to TLIF.
- 152 The pooled mean difference in operative time of other techniques was 31.88 minutes shorter than TLIF (MD=31.88
- 153 [95% CI 5.33, 58.44], p=0.02,  $I^2=92.0\%$ )

### 154 Blood loss

- 155 TLIF has less blood loss than PLIF 88.80 ml. No fusion has less blood loss among groups. Pooled mean difference
- 156 in blood loss showed no significant difference (MD=191.00 [95%CI -53.93, 435.93], p=0.13,  $I^2=90.0\%$ ).

# 157 Length of hospital stay

Length of hospital stay between subgroup were not significantly difference. Pooled mean difference in hospital stay was 0.12. (MD=0.12 [95% CI -0.30, 0.54], p=0.58,  $I^2=0.0\%$ ).

#### 160 Back and leg pain

- 161 Visual Analog Scale (VAS) for back were extracted from 6 studies. There was no difference between back pain at
- 162 last follow up in TLIF and other techniques group (MD=0.13 [95% CI -0.40, 0.66], p=0.62,  $l^2=82.0\%$ ). ALIF 163 (MD=1.20 [95% CI 0.53, 1.87], p<0.01) and no fusion techniques (MD=0.60 [95% CI 0.08, 1.12], p=0.02) were
- shown less back pain at last follow up. Visual Analog Scale (VAS) for leg was extracted from only PLF studies.
- 165 There was no difference between leg pain at last follow up in TLIF and PLF group (MD=-0.07 [95% CI -1.43, 1.30],
- 166  $p=0.92, I^2=77.0\%$ ).

#### 167 **ODI**

168 No difference in ODI was observed (MD=-4.82 [95% CI -11.72, 2.08], p=0.17,  $I^2=90.0\%$ ). Compared to TLIF, no 169 fusion group had higher ODI at last follow up (MD=-41.30 [95% CI -50.15, -32.45], p<0.001).

# 171 Table 2 Secondary outcomes

Outcomes	Studies	Patients	Statistical Method	Effect size [95% CI]
Infection	6	433	IV, random, 95% CI	RR=1.78 [95%CI 0.58, 5.46], $p=0.31, I^2=0.0\%$
Dural tear	7	570	IV, random, 95% CI	RR=1.19 [95% CI 0.49, 2.89], $p=0.70, I^2=0.0\%$
Operative time	6	353	IV, random, 95% CI	MD=31.88 [95% CI 5.33, 58.44], p=0.02, I <sup>2</sup> =92.0%
Blood loss	4	248	IV, random, 95% CI	191.00 [95%CI -53.93, 435.93], $p=0.13, I^2=90.0\%$
Length of Hospital stay	3	200	IV, random, 95% CI	MD=0.12 [95% CI -0.30, 0.54], p=0.58, I <sup>2</sup> =0.0%
VAS back at last follow up	6	335	IV, random, 95% CI	MD=0.13 [95% CI -0.40, 0.66], p=0.62, I <sup>2</sup> =82.0%
VAS leg at last follow up	2	150	IV, random, 95% CI	MD=-0.07 [95% CI -1.43, 1.30], p=0.92, I <sup>2</sup> =77.0%
ODI at last follow up	7	521	IV, random, 95% CI	MD=-4.82 [95% CI -11.72, 2.08], p=0.17, I <sup>2</sup> =90.0%

172 CI confidence interval; IV inverse variance; MD mean difference; RR risk ratio; VAS Visual Analog Scale

# 173 Discussion

Patients with degenerative lumbar spine disease require surgical intervention when the conservative treatments failed [7–10]. The operative methods are varyingly selected among spine surgeons. Therefore, the clinical outcomes esp. fusion rate, and other outcomes were reported in different studies. This systematic review and meta-analysis are to investigate the benefits and risks of lumbar interbody fusion, no fusion, and posterolateral fusion by comparing the fusion rate, clinical outcomes (VAS back, VAS leg, and ODI), parameters concerning operation (operative time, length of hospital stay, blood loss, revision) and complications in TLIF and other techniques for lumbar diseases.

- Findings from our study were similar to the previous systematic review that reported 89.1% fusion rate and 181 12.5% reoperation rate [33]. Manzur et al. reported 85.6% fusion rate on LLIF [34]. Similar to Tao et al. study 182 which PLIF compared with TLIF, demonstrated similar outcomes and complications [35].
- Surgical complications evaluated by total adverse events were not shown statistically significant differences among lumbar interbody fusion, no fusion, and posterolateral fusion. However, TLIF seems to be safer than PLIF and ALIF in neural, spinal and vascular events, similar to previous study by Chi et al. [36]. Nonetheless, Yavin et al. demonstrated more complications on fusion group compared to non-fusion group [37].

#### 187 Strength and limitations

The strength of this study was that we included only RCTs that showed no significant asymmetry which highlighted no evidence of publication bias on the fusion rate, total adverse events, and revision rate. However, the small number of RCT on TLIF was the limitation of our study. The heterogeneity of the enrolled studies was another limitation. Furthermore, sample group of some the same population as shown in table 1. We try to reduce the bias by excluded the repeated data from the analysis.

193 The overall lumbar spine disease were heterogenous in approach for each studies which may complicated 194 the results. Different surgical approach, experience and outcome measure were also observed. The outcomes were 195 referred to single level surgery which couldn't apply to multi-level diseases.

196

#### 197 Conclusion

The present systematic review and meta-analysis of RCTS demonstrated lower fusion rate of TLIF at 1 year but similar outcomes of TLIF with other techniques (no fusion, PLF, PLIF, ALIF, XLIF) for lumbar diseases in regards to fusion rate at 2 years, clinical outcomes and complications. Anticipate in randomized control trials are needed for selecting a surgical approach for lumbar spinal diseases.

Authors' contribution KW and KP contributed to the study conception and design. Material preparation and data collection were performed by KW and TN. Data analysis was performed by TN. All authors wrote the first draft of the manuscript, revised, and approved the final manuscript.

- 205 **Funding** No funding was received for this study.
- 206 Data Availability Statement All data generated or analyzed during this study are included in this published article
- 207 (and its supplementary information files).
- 208 Compliance with ethical standards
- 209 Conflicts of interest All authors declare that there are no conflicts of interest.

### 211 References

- Cloward RB. The treatment of ruptured lumbar intervertebral discs by vertebral body fusion. I. Indications,
   operative technique, after care. J Neurosurg. 1953 Mar;10(2):154-68. doi: 10.3171/jns.1953.10.2.0154.
   PMID: 13035484.
- Harms J, Rolinger H. Die operative Behandlung der Spondylolisthese durch dorsale Aufrichtung und ventrale Verblockung [A one-stager procedure in operative treatment of spondylolistheses: dorsal tractionreposition and anterior fusion (author's transl)]. Z Orthop Ihre Grenzgeb. 1982 May-Jun;120(3):343-7.
   German. doi: 10.1055/s-2008-1051624. PMID: 7113376.
- Foley KT, Lefkowitz MA. Advances in minimally invasive spine surgery. Clin Neurosurg. 2002;49:499 517. PMID: 12506566.
- Choy WJ, Abi-Hanna D, Cassar LP, Hardcastle P, Phan K, Mobbs RJ. History of Integral Fixation for
   Anterior Lumbar Interbody Fusion (ALIF): The Hartshill Horseshoe. World Neurosurg. 2019 Sep;129:394 doi: 10.1016/j.wneu.2019.06.134. Epub 2019 Jun 27. PMID: 31254709.
- Ozgur BM, Aryan HE, Pimenta L, Taylor WR. Extreme Lateral Interbody Fusion (XLIF): a novel surgical
   technique for anterior lumbar interbody fusion. Spine J. 2006 Jul-Aug;6(4):435-43. doi:
   10.1016/j.spinee.2005.08.012. PMID: 16825052.
- Goldstein CL, Macwan K, Sundararajan K, Rampersaud YR. Perioperative outcomes and adverse events of minimally invasive versus open posterior lumbar fusion: meta-analysis and systematic review. J Neurosurg Spine. 2016 Mar;24(3):416-27. doi: 10.3171/2015.2.SPINE14973. Epub 2015 Nov 13. PMID: 26565767.
- Phan K, Thayaparan GK, Mobbs RJ. Anterior lumbar interbody fusion versus transforaminal lumbar
  interbody fusion--systematic review and meta-analysis. Br J Neurosurg. 2015;29(5):705-11. doi:
  10.3109/02688697.2015.1036838. Epub 2015 May 12. PMID: 25968330.
- Joseph JR, Smith BW, La Marca F, Park P. Comparison of complication rates of minimally invasive
   transforaminal lumbar interbody fusion and lateral lumbar interbody fusion: a systematic review of the
   literature. Neurosurg Focus. 2015 Oct;39(4):E4. doi: 10.3171/2015.7.FOCUS15278. PMID: 26424344.
- 236 9. Chi KY, Cheng SH, Kuo YK, Lin EY, Kang YN. Safety of Lumbar Interbody Fusion Procedures for
   237 Degenerative Disc Disease: A Systematic Review With Network Meta-Analysis of Prospective Studies.

238 Global Spine J. 2020 Jul 28:2192568220938024. doi: 10.1177/2192568220938024. Epub ahead of print.

- **239** PMID: 32720524.
- 240 10. Zhang BF, Ge CY, Zheng BL, Hao DJ. Transforaminal lumbar interbody fusion versus posterolateral
  241 fusion in degenerative lumbar spondylosis: A meta-analysis. Medicine (Baltimore). 2016
  242 Oct;95(40):e4995. doi: 10.1097/MD.00000000004995. PMID: 27749558; PMCID: PMC5059060.
- 243 11. Lan T, Hu SY, Zhang YT, Zheng YC, Zhang R, Shen Z, Yang XJ. Comparison Between Posterior Lumbar
- Interbody Fusion and Transforaminal Lumbar Interbody Fusion for the Treatment of Lumbar Degenerative
  Diseases: A Systematic Review and Meta-Analysis. World Neurosurg. 2018 Apr;112:86-93. doi:
  10.1016/j.wneu.2018.01.021. Epub 2018 Jan 31. PMID: 29367001.
- 12. Keorochana G, Setrkraising K, Woratanarat P, Arirachakaran A, Kongtharvonskul J. Clinical outcomes
  after minimally invasive transforaminal lumbar interbody fusion and lateral lumbar interbody fusion for
  treatment of degenerative lumbar disease: a systematic review and meta-analysis. Neurosurg Rev. 2018
  Jul;41(3):755-770. doi: 10.1007/s10143-016-0806-8. Epub 2016 Dec 24. PMID: 28013419.
- 251 13. Zhang Q, Yuan Z, Zhou M, Liu H, Xu Y, Ren Y. A comparison of posterior lumbar interbody fusion and
  252 transforaminal lumbar interbody fusion: a literature review and meta-analysis. BMC Musculoskelet Disord.
  253 2014 Nov 5;15:367. doi: 10.1186/1471-2474-15-367. PMID: 25373605; PMCID: PMC4232693.
- 14. Lan T, Hu SY, Zhang YT, Zheng YC, Zhang R, Shen Z, Yang XJ. Comparison Between Posterior Lumbar
  Interbody Fusion and Transforaminal Lumbar Interbody Fusion for the Treatment of Lumbar Degenerative
  Diseases: A Systematic Review and Meta-Analysis. World Neurosurg. 2018 Apr;112:86-93. doi:
  10.1016/j.wneu.2018.01.021. Epub 2018 Jan 31. PMID: 29367001.
- 258 15. Teng I, Han J, Phan K, Mobbs R. A meta-analysis comparing ALIF, PLIF, TLIF and LLIF. J Clin
  259 Neurosci. 2017 Oct;44:11-17. doi: 10.1016/j.jocn.2017.06.013. Epub 2017 Jul 1. PMID: 28676316.
- 260 16. Challier V, Boissiere L, Obeid I, Vital JM, Castelain JE, Bénard A, Ong N, Ghailane S, Pointillart V,
   261 Mazas S, Mariey R, Gille O. One-Level Lumbar Degenerative Spondylolisthesis and Posterior Approach:
   262 Is Transforaminal Lateral Interbody Fusion Mandatory?: A Randomized Controlled Trial With 2-Year
- 263
   Follow-Up. Spine (Phila Pa 1976). 2017 Apr 15;42(8):531-539. doi: 10.1097/BRS.00000000001857.
- 264 PMID: 27548582.


265	17. Christensen A, Høy K, Bünger C, Helmig P, Hansen ES, Andersen T, Søgaard R. Transforaminal lumbar
266	interbody fusion vs. posterolateral instrumented fusion: cost-utility evaluation along side an RCT with a 2-
267	year follow-up. Eur Spine J. 2014 May;23(5):1137-43. doi: 10.1007/s00586-014-3238-6. Epub 2014 Feb
268	21. PMID: 24557326.

- 269 18. El Shazly AA, El Wardany MA, Morsi AM. Recurrent lumbar disc herniation: A prospective comparative
  270 study of three surgical management procedures. *Asian J Neurosurg*. 2013;8(3):139-146. doi:10.4103/1793271 5482.121685
- Etemadifar MR, Hadi A, Masouleh MF. Posterolateral instrumented fusion with and without transforaminal
  lumbar interbody fusion for the treatment of adult isthmic spondylolisthesis: A randomized clinical trial
  with 2-year follow-up. J Craniovertebr Junction Spine. 2016 Jan-Mar;7(1):43-9. doi: 10.4103/09748237.176623. PMID: 27041885; PMCID: PMC4790148.
- 276 20. Fariborz, Samini MD; Gharedaghi, Mohammad MD; Khosravi, Abbas F. MD; Samini, Mohammad MS
  277 Comparison of Results of 4 Methods of Surgery in Grade 1 Lumbosacral Spondylolisthesis, Neurosurgery
  278 Quarterly: February 2016 Volume 26 Issue 1 p 14-18 doi: 10.1097/WNQ.000000000000197
- 279 21. Hoff EK, Strube P, Pumberger M, Zahn RK, Putzier M. ALIF and total disc replacement versus 2-level
  280 circumferential fusion with TLIF: a prospective, randomized, clinical and radiological trial. Eur Spine J.
  281 2016 May;25(5):1558-1566. doi: 10.1007/s00586-015-3852-y. Epub 2015 Mar 7. PMID: 25749689.
- 282 22. Høy K, Bünger C, Niederman B, Helmig P, Hansen ES, Li H, Andersen T. Transforaminal lumbar
  283 interbody fusion (TLIF) versus posterolateral instrumented fusion (PLF) in degenerative lumbar disorders:
  284 a randomized clinical trial with 2-year follow-up. Eur Spine J. 2013 Sep;22(9):2022-9
- 285 23. Høy K, Truong K, Andersen T, Bünger C. Addition of TLIF does not improve outcome over standard
  286 posterior instrumented fusion. 5-10 years long-term Follow-up: results from a RCT. Eur Spine J. 2017
  287 Mar;26(3):658-665. doi: 10.1007/s00586-016-4592-3. Epub 2016 May 7. PMID: 27155825.
- 24. Høy K, Grycel B, Andersen T, Bünger C. Does transforaminal lumbar interbody fusion produce leg pain?Results from a RCT. J Orthop Surg (Hong Kong). 2019 Sep-Dec;27(3):2309499019869469. doi:
  10.1177/2309499019869469. PMID: 31530081.
- 25. Isaacs RE, Sembrano JN, Tohmeh AG; SOLAS Degenerative Study Group. Two-Year Comparative
   Outcomes of MIS Lateral and MIS Transforaminal Interbody Fusion in the Treatment of Degenerative

- Spondylolisthesis: Part II: Radiographic Findings. Spine (Phila Pa 1976). 2016 Apr;41 Suppl 8:S133-44.
  doi: 10.1097/BRS.00000000001472. PMID: 26839992.
- 26. Jalalpour K, Neumann P, Johansson C, Hedlund R. A Randomized Controlled Trial Comparing
   Transforaminal Lumbar Interbody Fusion and Uninstrumented Posterolateral Fusion in the Degenerative
   Lumbar Spine. Global Spine J. 2015 Aug;5(4):322-8. doi: 10.1055/s-0035-1549033.
- 27. Li FC, Chen QX, Chen WS, Xu K, Wu QH, Chen G. Posterolateral lumbar fusion versus transforaminal
  lumbar interbody fusion for the treatment of degenerative lumbar scoliosis. J Clin Neurosci. 2013
  Sep;20(9):1241-5. doi: 10.1016/j.jocn.2012.10.031. Epub 2013 Jul 1. PMID: 23827174.
- 28. Putzier M, Hartwig T, Hoff EK, Streitparth F, Strube P. Minimally invasive TLIF leads to increased muscle
  sparing of the multifidus muscle but not the longissimus muscle compared with conventional PLIF-a
  prospective randomized clinical trial. Spine J. 2016 Jul;16(7):811-9. doi: 10.1016/j.spinee.2015.07.460.
  Epub 2015 Jul 30. PMID: 26235468.
- Sembrano JN, Tohmeh A, Isaacs R; SOLAS Degenerative Study Group. Two-year Comparative Outcomes
  of MIS Lateral and MIS Transforaminal Interbody Fusion in the Treatment of Degenerative
  Spondylolisthesis: Part I: Clinical Findings. Spine (Phila Pa 1976). 2016 Apr;41 Suppl 8:S123-32. doi:
  10.1097/BRS.00000000001471. PMID: 26825788.
- 30. Yang EZ, Xu JG, Liu XK, Jin GY, Xiao W, Zeng BF, Lian XF. An RCT study comparing the clinical and
  radiological outcomes with the use of PLIF or TLIF after instrumented reduction in adult isthmic
  spondylolisthesis. Eur Spine J. 2016 May;25(5):1587-1594. doi: 10.1007/s00586-015-4341-z. Epub 2015
  Dec 9. PMID: 26649555.
- 313 31. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for
  314 Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097.
  315 doi:10.1371/journal.pmed1000097
- 316 32. Sterne J, Savović J, Page M et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised
  317 trials. BMJ 366:i4898
- 318 33. Phillips FM, Slosar PJ, Youssef JA, Andersson G, Papatheofanis F. Lumbar spine fusion for chronic low
  back pain due to degenerative disc disease: a systematic review. *Spine (Phila Pa 1976)*. 2013;38(7):E409E422. doi:10.1097/BRS.0b013e3182877f11

- 321 34. Manzur MK, Steinhaus ME, Virk SS, Jivanelli B, Vaishnav AS, McAnany SJ, Albert TJ, Iyer S, Gang CH,
- Qureshi SA. Fusion rate for stand-alone lateral lumbar interbody fusion: a systematic review. Spine J. 2020
   Nov;20(11):1816-1825. doi: 10.1016/j.spinee.2020.06.006. Epub 2020 Jun 11. PMID: 32535072.
- 324 35. Lan T, Hu SY, Zhang YT, et al. Comparison Between Posterior Lumbar Interbody Fusion and
- Transforaminal Lumbar Interbody Fusion for the Treatment of Lumbar Degenerative Diseases: A
  Systematic Review and Meta-Analysis. *World Neurosurg.* 2018;112:86-93.
- doi:10.1016/j.wneu.2018.01.021
- 36. Chi KY, Cheng SH, Kuo YK, Lin EY, Kang YN. Safety of Lumbar Interbody Fusion Procedures for
  Degenerative Disc Disease: A Systematic Review With Network Meta-Analysis of Prospective
  Studies. *Global Spine J.* 2020;2192568220938024. doi:10.1177/2192568220938024
- 331 37. Yavin D, Casha S, Wiebe S, et al. Lumbar Fusion for Degenerative Disease: A Systematic Review and
   332 Meta-Analysis. *Neurosurgery*. 2017;80(5):701-715. doi:10.1093/neuros/nyw162

333



Studies included in quantitative synthesis (meta-analysis) (n = 15)

Fig. 1 Flowchart of this systematic review with meta-analysis of prospective studies. RCTs, randomized clinical trials




Fig. 2 The risk of bias of each included randomized controlled trial. Low risk is presented as green dot, some concerns as yellow dot, and high risk as red dot





Fig. 3 The risk of bias of included randomized controlled trials. Bars show percentages across all included RCTs

	TLI	F	Other techn	iques		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% Cl
1.2.1 PLF								
Fariborz 2016 Subtotal (95% CI)	11	15 15	26	30 30	20.1% 20.1%	0.85 [0.60, 1.18] 0.85 [0.60, 1.18]	2016	-
Total events	11		26					
Heterogeneity: Not a	pplicable							
Test for overall effect	Z = 0.97	(P = 0.3	3)					
1.2.2 PLIF								
Putzier 2016	16	24	17	23	16.3%	0.90 [0.62, 1.31]	2016	
Fariborz 2016	12	15	26	30	27.1%	0.92 [0.69, 1.23]	2016	
Subtotal (95% CI)		39		53	43.5%	0.92 [0.73, 1.15]		-
Total events	28		43					
Heterogeneity: Tau <sup>2</sup> =	= 0.00; Ch	$i^2 = 0.01$	, df = 1 (P = 1	0.92); l² =	= 0%			
Test for overall effect	Z=0.76	(P = 0.4)	5)					
1.2.3 XLIF								
Isaacs 2016	17	23	25	25	36.4%	0.74 [0.58, 0.95]	2016	
Subtotal (95% CI)		23		25	36.4%	0.74 [0.58, 0.95]		-
Total events	17		25					
Heterogeneity: Not a	pplicable							
Test for overall effect	Z = 2.33	(P = 0.0	2)					
Total (95% CI)		77		108	100.0%	0.84 [0.72, 0.97]		•
Total events	56		94					
Heterogeneity: Tau <sup>2</sup> =	= 0.00; Ch	i <sup>2</sup> = 1.48	6, df = 3 (P = )	0.69); I <sup>2</sup> =	= 0%			0.2 0.5 1 2
Test for overall effect	Z= 2.34	(P = 0.0)	2)					Favours Other techniques Favours TLIF
Test for subgroup dif	ferences:	Chi <sup>2</sup> = 1	.45, df = 2 (F	= 0.48),	I <sup>2</sup> = 0%			ravours outer techniques ravours rulf

**Fig. 4** Forest plot and tabulated data illustrating the risk ratio (RR) for fusion rate at 1 year between TLIF, PLF, PLIF and XLIF showing that Other techniques had a better arm fusion rate at 1 year and was therefore superior to TLIF in this respect. *CI* confidence interval; *df* degrees of freedom



**Fig. 5** Forest plot and tabulated data illustrating the risk ratio (RR) for fusion rate at 2 years between TLIF, PLF, PLIF and XLIF showing that there was no significant difference of fusion rate at 2 years between procedures. *CI* confidence interval; *df* degrees of freedom

	TLIF		Other techn			Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	Year	r IV, Random, 95% Cl
9.1.1 PLF								
Høy 2013	7	51	3	49	10.7%	2.24 [0.61, 8.18]	2013	3
Li 2013	5	19	2	18	7.9%	2.37 [0.52, 10.70]	2013	3
EIShazly 2013	2	8	2	15	5.8%	1.88 [0.32, 10.92]	2013	3
Jalalpour 2015	4	68	4	67	9.9%	0.99 [0.26, 3.78]	2015	5
Fariborz 2016	1	10	1	30	2.5%	3.00 [0.21, 43.66]	2016	6
Etemadifar 2016	1	25	0	25	1.8%	3.00 [0.13, 70.30]	2016	6
Challier 2017	3	30	6	30	10.8%	0.50 [0.14, 1.82]	2017	7
Subtotal (95% CI)		211		234	49.5%	1.39 [0.76, 2.54]		-
Total events	23		18					
Heterogeneity: Tau <sup>2</sup> =	0.00: Chi	<sup>2</sup> = 4.3	2. $df = 6 (P = 0)$	0.63); I <sup>2</sup> =	: 0%			
Test for overall effect								
9.1.2 PLIF								
Fariborz 2016	1	10	2	30	3.4%	1.50 [0.15, 14.83]	2016	6
Putzier 2016	1	24	2	23	3.3%			
Yang 2016	3	32	4	34	8.9%	0.80 [0.19, 3.29]		
Subtotal (95% CI)	5	66	-	87	15.7%	0.82 [0.28, 2.40]	2010	
Total events	5		8					
Heterogeneity: Tau² = Test for overall effect:				0.79); l² =	: 0%			
9.1.3 XLIF								
Sembrano 2016	5	26	11	29	21.5%	0.51 [0.20, 1.27]	2016	6
Subtotal (95% CI)		26		29	21.5%	0.51 [0.20, 1.27]		-
Total events	5		11					
Heterogeneity: Not ap	plicable							
Test for overall effect		(P = 0.1	5)					
9.1.4 No fusion								
EIShazly 2013	2	7	8	15	11.3%	0.54 [0.15, 1.89]	2013	3
Fariborz 2016	0	10	3	30	2.2%	0.40 [0.02, 7.19]		
Subtotal (95% CI)		17		45	13.4%	0.51 [0.16, 1.63]	2010	
Total events	2		11					
Heterogeneity: Tau <sup>2</sup> =	0.00; Chi	r= 0.0	3, df = 1 (P = 1	0.86); I <sup>2</sup> =	: 0%			
Test for overall effect	Z=1.14 (	(P = 0.2	26)					
Total (95% CI)		320		395	100.0%	0.90 [0.59, 1.38]		•
Total events	35		48					
Heterogeneity: Tau <sup>2</sup> =	and the second second second	= 9 2	and are and a subscription of	0.68)	= 0%			
Test for overall effect				0.00/11	0.0			0.01 0.1 1 10
Loor of overall ellect			4.44. df = 3 (P					Favours TLIF Favours Other technig

**Fig. 6** Forest plot and tabulated data illustrating the risk ratio (RR) for adverse events between TLIF, PLF, PLIF, XLIF and no fusion showing that there was no significant difference of adverse events between procedures. *CI* confidence interval; *df* degrees of freedom

	TLIF		Other tech	nique		<b>Risk Ratio</b>			Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	IV, Random, 95% CI	Year		IV, Random, 95% Cl
2.1.1 PLF									
Li 2013	0	19	0	18		Not estimable	2013		
Jalalpour 2015	5	68	12	67	34.7%	0.41 [0.15, 1.10]	2015		
Challier 2017	1	30	3	30	11.8%	0.33 [0.04, 3.03]	2017		•
Høy 2017	14	44	11	44	47.2%	1.27 [0.65, 2.49]	2017		
Subtotal (95% CI)		161		159	93.7%	0.69 [0.28, 1.74]			
Total events	20		26						
Heterogeneity: Tau <sup>2</sup> =	= 0.33; Chi	$r^{2} = 4.11$	7, df = 2 (P =	0.12); P	= 52%				
Test for overall effect	Z=0.78	(P = 0.4)	3)						
2.1.2 XLIF									
Sembrano 2016	1	26	0	29	6.3%	3.33 [0.14, 78.42]	2016		
Subtotal (95% CI)		26		29	6.3%	3.33 [0.14, 78.42]			
Total events	1		0						
Heterogeneity: Not ap	oplicable								
Test for overall effect	Z=0.75	(P = 0.4	5)						
Total (95% CI)		187		188	100.0%	0.78 [0.34, 1.79]			-
Total events	21		26						
Heterogeneity: Tau <sup>2</sup> =	0.26: Chi	<sup>2</sup> = 4.80	8. df = 3 (P =	0.18); P	= 39%			-	
Test for overall effect								0.01	0.1 1 10 100
Test for subgroup dif				D - 0.26	N IZ - 000				Favours TLIF Favours Other techniques

Fig. 7 Forest plot and tabulated data illustrating the risk ratio (RR) for revision rate between TLIF, PLF and XLIF

showing that there was no significant difference of revision rate between procedures. CI confidence interval;

df degrees of freedom